The China MedTech Edge: December 2025 Intelligence Briefing

Delivering essential intelligence on China’s MedTech ecosystem: Policy & Compliance, Innovation, Global Strategy and beyond.

January 2, 2026

December 2025 marked a pivotal month for the Chinese medical device industry, characterized by a strategic “dual-track” advancement in policy optimization and high-frontier innovation. Regulatory bodies at both national and provincial levels intensified efforts to streamline market entry, exemplified by Guangdong’s “zero-supplementation” registration pilot and the National Medical Products Administration’s (NMPA) updated guidelines for global exports. Technically, the industry achieved “0 to 1” breakthroughs in neuromodulation and brain-computer interfaces (BCI), with the world’s first BCI-based system for opioid addiction receiving marketing approval. Beyond domestic milestones, the sector demonstrated a maturing global strategy, shifting from simple product exports to a comprehensive ecosystem involving overseas production bases and regional service hubs. Supported by a capital market that remains highly focused on core disruptive technologies, the month concludes with China firmly positioned as a rising global leader in high-end medical manufacturing.

I. Regulatory & Policy Intelligence

  • Guangdong’s “Zero-Supplementation” Pilot: Launched on December 18, this pre-consultation service for Class II devices aims to resolve documentation issues before official submission, effectively replacing the traditional iterative review cycle with a “one-time pass” model to accelerate market entry.
  • Export Infrastructure: A newly revised Regulation on the Management of Medical Device Export Sales Certificates was released on December 25, providing a more standardized and transparent official certification path for Chinese firms targeting international markets (effective May 2026).
  • High-End Priority List: The NMPA released the 2025 Catalog of High-End Medical Devices for Priority Approval, specifically targeting breakthrough categories such as Boron Neutron Capture Therapy (BNCT) systems, ultra-high field MRI, and implantable BCI devices.

II. Spotlight Innovation: The “New Era” of Neuromodulation

The most significant clinical milestone this month was the NMPA approval of SceneRay Medical’s Implantable Deep Brain Stimulation (DBS) System.

  • Technical Breakthrough: It is the first invasive BCI product globally approved to treat refractory moderate-to-severe opioid addiction.
  • Mechanism: The system delivers precise micro-pulses to the Nucleus Accumbens (NAc) and the Anterior Limb of the Internal Capsule (ALIC) to regulate addiction-related neural circuits.
  • Clinical Efficacy: Long-term data indicates that after 1.5 to 2 years of treatment, patients can maintain abstinence even after the device is deactivated, filling a critical gap in physical intervention for psychiatric disorders.

III. Clinical & Research Frontiers

  • “Three-Full” BCI Success: Shanghai NeuroXess successfully completed the first human trial of a “fully implanted, fully wireless, and fully functional” BCI. The subject, a patient with high-level paraplegia, achieved intent-based control of digital and physical devices (e.g., wheelchairs and robotic hands) via the self-developed XessOs system.
  • Micro-Robotics: Research teams at SIAT (Shenzhen) developed Helixoft, a magnetic micro-robotic system capable of programmable stiffness adjustment at the micron scale, designed for seamless integration into commercial surgical catheters.

IV. Internationalization & Capital Markets

  • South Asia Expansion: A major supply-demand matchmaking event in Beijing resulted in $14.25 million (approx. 100 million RMB) in immediate procurement orders for surgical and diagnostic equipment.
  • Strategic Outbound Investment: Zhonghong Pulin announced a billion-RMB global upgrade, planning two major production bases in Southeast Asia to transition from OEM manufacturing to a global brand operator.
  • IPO Momentum: Briohealth Solutions, a leader in fully magnetically levitated artificial hearts, has had its STAR Market IPO application accepted, with funds earmarked for U.S. clinical trials and global commercialization.